An Observational Study to Assess Ubrogepant Tablets and Atogepant Tablets to Treat Migraine in Adult Participants (COBRA)
Status
Conditions
Details and patient eligibility
About
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. This study will evaluate how effective the use of ubrogepant and atogepant is in treating adult participants with migraine.
Urogepant (Ubrelvy) and Atogepant (Qulipta) are approved drugs for treatment of migraine in adults in the US. Approximately 200 adult participants who are prescribed Ubrogepant or atogepant by their doctors will be enrolled in this study in Israel.
Participants will receive ubrogepant oral tablets or atogepant oral tablets as prescribed by their physician. Participants will be followed for 90 days.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Confirmed diagnosis of migraine according to the ICHD-3 upon judgement of the treating physician
- The patients should be naive to the designated treatment
- Ability to fill an e-diary app
Exclusion criteria
- Patients who cannot be treated with UBRO or ATO according to the applicable approved label
- Patients participating in a concurrent clinical interventional study or within the last 30 days
- Patients who were previously treated with rimegepant will be excluded from the study
Trial design
200 participants in 2 patient groups
Trial contacts and locations
Loading...
Central trial contact
Tal Nevo
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal